DIASORIN S.P.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.58 EUR | +0.28% |
|
+1.70% | +0.36% |
| May. 03 | Funds cut short on Azimut Holding | AN |
| Apr. 24 | Citadel Advisors initiates short on STMicroelectronics. | AN |
This Alphavalue article, the European leader in independent research, is only available to subscribers .Alphavalue is exclusively on MarketScreener. To unlock the article, SUBSCRIBE!
Already a customer? Log In
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc.
At the end of 2023, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.
Calendar
2024-05-09
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
93.32
EUR
Average target price
97.21
EUR
Spread / Average Target
+4.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.36% | 5.37B | |
| -0.50% | 12.64B | |
| -1.64% | 8.37B | |
| +22.42% | 5.26B | |
| -0.09% | 4.58B | |
| -52.84% | 3.16B | |
| +20.02% | 2.89B | |
| -8.17% | 2.22B | |
| -2.45% | 1.91B | |
| +6.45% | 1.65B |
- Stock Market
- Equities
- DIA Stock
- News DiaSorin S.p.A.
- DiaSorin: Profitability guidance miss; dreams inching towards reality